MCUJF MEDICURE INC IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1133519 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | 2025Q1*2025-03-31 | 2024Q1*2024-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | 5.48M | 5.69M |
| Cost of revenue | 2.64M | 1.80M |
| Gross profit | 2.84M | 3.90M |
| R&D expense | 570,000 | 676,000 |
| SG&A expense | 1.10M | 1.21M |
| Pretax income | -656,000 | 82,000 |
| Income tax | 38,000 | -31,000 |
| Net income | -694,000 | 51,000 |
| EPS (basic) | -0.07 | 0.00 |
| EPS (diluted) | -0.07 | 0.00 |
| Weighted avg. shares (diluted) | 10.44M | 10.50M |
| Balance sheet | ||
| Cash & equivalents | 7.22M | — |
| Receivables | 4.46M | — |
| Inventory | 3.91M | — |
| Current assets | 15.78M | — |
| PP&E, netmay include right-of-use assets (IFRS) | 1.00M | — |
| Goodwill | 3.93M | — |
| Intangibles | 8.96M | — |
| Total assets | 29.78M | — |
| Current liabilities | 9.24M | — |
| Total liabilities | 9.68M | — |
| Shareholders' equity | 20.09M | 20.50M |
| Cash flow statement | ||
| Operating cash flow | 656,000 | -132,000 |
| Investing cash flow | -542,000 | -87,000 |
| Financing cash flow | -89,000 | -76,000 |
| Depreciation & amortization | 114,000 | 104,000 |
| Stock-based compensation | 36,000 | 58,000 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.